Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
BLR Bio LLC
FibroGen Inc
InnoBioscience LLC
Limil BioSciences Inc
OliX Pharmaceuticals Inc
Phio Pharmaceuticals Corp
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
BLR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-DMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-201A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-301D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamrevlumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones
Featured News & Press Releases
Nov 18, 2019: Limil presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmory Arterial Hypertension
Nov 12, 2019: Limil BioSciences presents new preclinical data on PBI-4050
Nov 11, 2019: Limil Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
Oct 25, 2019: Limil BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
Oct 24, 2019: Limil BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
Oct 23, 2019: FibroGen announces first patient dosed in LAPIS, a phase 3 clinical trial of Pamrevlumab for the treatment of patients with locally advanced pancreatic cancer
Sep 30, 2019: FibroGen announces publication in the Lancet Respiratory Medicine of positive Pamrevlumab efficacy and safety data for the praise phase 2 study in Idiopathic Pulmory Fibrosis
Jul 22, 2019: FibroGen announces first patient dosed in ZEPHYRUS, a phase 3 clinical trial of pamrevlumab for the treatment of patients with idiopathic pulmory fibrosis
Jun 28, 2019: FibroGen to present interim phase 2 data on pamrevlumab in subjects with duchenne muscular dystrophy at the parent project muscular dystrophy 2019 annual conference
Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
Apr 15, 2019: FibroGen receives Orphan Drug Desigtion from the U.S. FDA For Pamrevlumab for the treatment of Duchenne Muscular Dystrophy
Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
Sep 12, 2018: FibroGen receives Fast Track desigtion from the U.S. FDA for Pamrevlumab for the Treatment of idiopathic pulmory fibrosis
Aug 10, 2018: Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in jourl of pharmacology and experimental therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BLR Bio LLC, H2 2019
Pipeline by FibroGen Inc, H2 2019
Pipeline by InnoBioscience LLC, H2 2019
Pipeline by Liminal BioSciences Inc, H2 2019
Pipeline by OliX Pharmaceuticals Inc, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019